GB0507298D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0507298D0
GB0507298D0 GBGB0507298.8A GB0507298A GB0507298D0 GB 0507298 D0 GB0507298 D0 GB 0507298D0 GB 0507298 A GB0507298 A GB 0507298A GB 0507298 D0 GB0507298 D0 GB 0507298D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0507298.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34610935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0507298(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0507298.8A priority Critical patent/GB0507298D0/en
Publication of GB0507298D0 publication Critical patent/GB0507298D0/en
Priority to MYPI20094250A priority patent/MY149070A/en
Priority to MYPI20061558A priority patent/MY142474A/en
Priority to GT200600144AK priority patent/GT200600144AA/es
Priority to ARP060101392A priority patent/AR053047A1/es
Priority to PE2006000379A priority patent/PE20061306A1/es
Priority to PE2009000810A priority patent/PE20091366A1/es
Priority to GT200600144A priority patent/GT200600144A/es
Priority to SA109300363A priority patent/SA109300363B1/ar
Priority to SA06270089A priority patent/SA06270089B1/ar
Priority to KR1020077023171A priority patent/KR100990783B1/ko
Priority to RU2007141566/04A priority patent/RU2435760C2/ru
Priority to NZ560964A priority patent/NZ560964A/en
Priority to MX2007012592A priority patent/MX2007012592A/es
Priority to SI200631844T priority patent/SI2468732T1/sl
Priority to DK06724185.1T priority patent/DK1871749T3/da
Priority to KR1020097022601A priority patent/KR101162827B1/ko
Priority to PL12158895T priority patent/PL2468732T3/pl
Priority to SG2011089851A priority patent/SG177182A1/en
Priority to EP12158899A priority patent/EP2463278A1/en
Priority to CN2012102580549A priority patent/CN102807531A/zh
Priority to CN2006800116660A priority patent/CN101155789B/zh
Priority to EP12158895.8A priority patent/EP2468732B1/en
Priority to TW101133845A priority patent/TWI440461B/zh
Priority to PT121588958T priority patent/PT2468732E/pt
Priority to JP2008505790A priority patent/JP4898783B2/ja
Priority to EP12158903A priority patent/EP2476671A1/en
Priority to US11/911,040 priority patent/US7655666B2/en
Priority to TW095112596A priority patent/TWI385158B/zh
Priority to EP06724185A priority patent/EP1871749B1/en
Priority to ES06724185T priority patent/ES2392542T3/es
Priority to NZ590463A priority patent/NZ590463A/en
Priority to SI200631459T priority patent/SI1871749T1/sl
Priority to ZA200807421A priority patent/ZA200807421B/en
Priority to IN785DEN2012 priority patent/IN2012DN00785A/en
Priority to ES12158895.8T priority patent/ES2524316T3/es
Priority to AU2006233639A priority patent/AU2006233639B2/en
Priority to CA 2601986 priority patent/CA2601986C/en
Priority to DK12158895.8T priority patent/DK2468732T3/da
Priority to RU2011131276/04A priority patent/RU2509764C2/ru
Priority to PT06724185T priority patent/PT1871749E/pt
Priority to PCT/EP2006/003251 priority patent/WO2006108591A1/en
Priority to HRP20120867TT priority patent/HRP20120867T1/hr
Priority to JO200693A priority patent/JO2770B1/en
Priority to HK08103724.9A priority patent/HK1113790B/en
Priority to PL06724185T priority patent/PL1871749T3/pl
Priority to BRPI0608617-9A priority patent/BRPI0608617A2/pt
Priority to ZA200707111A priority patent/ZA200707111B/xx
Priority to IL185544A priority patent/IL185544A/en
Priority to TNP2007000383A priority patent/TNSN07383A1/en
Priority to MA30330A priority patent/MA29411B1/fr
Priority to NO20075749A priority patent/NO20075749L/no
Priority to US12/569,402 priority patent/US8012988B2/en
Priority to AU2011200888A priority patent/AU2011200888B2/en
Priority to US13/192,816 priority patent/US8513268B2/en
Priority to JP2011209578A priority patent/JP5525500B2/ja
Priority to ECSP12007795 priority patent/ECSP12007795A/es
Priority to IL220682A priority patent/IL220682A/en
Priority to CY20121101042T priority patent/CY1113573T1/el
Priority to US13/932,173 priority patent/US20130296332A1/en
Priority to HRP20141116TT priority patent/HRP20141116T1/hr
Priority to CY20141100963T priority patent/CY1115767T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C207/00—Compounds containing nitroso groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/64—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/66—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/18—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups bound to carbon atoms of carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C265/00—Derivatives of isocyanic acid
    • C07C265/12—Derivatives of isocyanic acid having isocyanate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Dental Preparations (AREA)
GBGB0507298.8A 2005-04-11 2005-04-11 Organic compounds Ceased GB0507298D0 (en)

Priority Applications (62)

Application Number Priority Date Filing Date Title
GBGB0507298.8A GB0507298D0 (en) 2005-04-11 2005-04-11 Organic compounds
MYPI20094250A MY149070A (en) 2005-04-11 2006-04-06 1h-quinazoline-2,4-diones
MYPI20061558A MY142474A (en) 2005-04-11 2006-04-06 1h-quinazoline-2,4-diones
GT200600144AK GT200600144AA (es) 2005-04-11 2006-04-07 1h-quinazolin-2,4-dionas (solicitud fraccionaria, derivada de la solicitud de patente de invencion pi-2006-00144)
ARP060101392A AR053047A1 (es) 2005-04-11 2006-04-07 1h-quinazolin-2,4-dionas como ligandos del receptor ampa
PE2006000379A PE20061306A1 (es) 2005-04-11 2006-04-07 1h-quinazolin-2,4-dionas
PE2009000810A PE20091366A1 (es) 2005-04-11 2006-04-07 1h-quinazolin-2,4-dionas
GT200600144A GT200600144A (es) 2005-04-11 2006-04-07 1h-quinazolin-2,4-dionas
SA109300363A SA109300363B1 (ar) 2005-04-11 2006-04-09 1h–كينازولين–2، 4–دايونات
SA06270089A SA06270089B1 (ar) 2005-04-11 2006-04-09 1h–كينازولين–2، 4–دايونات
KR1020077023171A KR100990783B1 (ko) 2005-04-11 2006-04-10 1ｈ-퀴나졸린-2,4-디온 및 그의 ａｍｐａ-수용체리간드로서의 용도
RU2007141566/04A RU2435760C2 (ru) 2005-04-11 2006-04-10 1н-хиназолин-2,4-дионы
NZ560964A NZ560964A (en) 2005-04-11 2006-04-10 1H-Quinazoline-2,4-diones and their use as AMPA-receptor ligands
MX2007012592A MX2007012592A (es) 2005-04-11 2006-04-10 1h-quinazolin-2,4-dionas y su uso como ligandos del receptor de ampa.
SI200631844T SI2468732T1 (sl) 2005-04-11 2006-04-10 1H-kinazolin-2,4-dioni
DK06724185.1T DK1871749T3 (da) 2005-04-11 2006-04-10 Selurampanel
KR1020097022601A KR101162827B1 (ko) 2005-04-11 2006-04-10 1ｈ-퀴나졸린-2,4-디온 및 그의 ａｍｐａ-수용체 리간드로서의 용도
PL12158895T PL2468732T3 (pl) 2005-04-11 2006-04-10 1H-Chinazolino-2,4-diony
SG2011089851A SG177182A1 (en) 2005-04-11 2006-04-10 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands
EP12158899A EP2463278A1 (en) 2005-04-11 2006-04-10 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands
CN2012102580549A CN102807531A (zh) 2005-04-11 2006-04-10 1h-喹唑啉-2,4-二酮及其作为ampa-受体配体的用途
CN2006800116660A CN101155789B (zh) 2005-04-11 2006-04-10 1h-喹唑啉-2,4-二酮及其作为ampa-受体配体的用途
EP12158895.8A EP2468732B1 (en) 2005-04-11 2006-04-10 1H-Quinazoline-2,4-diones
TW101133845A TWI440461B (zh) 2005-04-11 2006-04-10 １ｈ-喹唑啉-２，４-二酮
PT121588958T PT2468732E (pt) 2005-04-11 2006-04-10 1h-quinazolino-2,4-dionas e sua utilização como ligandos dos receptores ampa
JP2008505790A JP4898783B2 (ja) 2005-04-11 2006-04-10 １ｈ−キナゾリン−２，４−ジオンおよびａｍｐａ受容体リガンドとしてのそれらの使用
EP12158903A EP2476671A1 (en) 2005-04-11 2006-04-10 1H-Quinazoline-2,4-diones
US11/911,040 US7655666B2 (en) 2005-04-11 2006-04-10 Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands
TW095112596A TWI385158B (zh) 2005-04-11 2006-04-10 １ｈ-喹唑啉-２，４-二酮
EP06724185A EP1871749B1 (en) 2005-04-11 2006-04-10 Selurampanel
ES06724185T ES2392542T3 (es) 2005-04-11 2006-04-10 Selurampanel
NZ590463A NZ590463A (en) 2005-04-11 2006-04-10 Selected 1H-quinazoline-2,4-diones and their use as AMPA-receptor ligands
SI200631459T SI1871749T1 (sl) 2005-04-11 2006-04-10 Selurampanel
ZA200807421A ZA200807421B (en) 2005-04-11 2006-04-10 1H-quinazoline-2,4-diones and their use as AMPA-receptor ligands
IN785DEN2012 IN2012DN00785A (enExample) 2005-04-11 2006-04-10
ES12158895.8T ES2524316T3 (es) 2005-04-11 2006-04-10 1H-Quinazolina-2,4-dionas
AU2006233639A AU2006233639B2 (en) 2005-04-11 2006-04-10 1H-Quinazoline-2,4-diones and their use as AMPA-receptor ligands
CA 2601986 CA2601986C (en) 2005-04-11 2006-04-10 1h-quinazoline-2,4-diones and their use as ampa-receptor ligands
DK12158895.8T DK2468732T3 (da) 2005-04-11 2006-04-10 1H-Quinazolin-2,4-dioner
RU2011131276/04A RU2509764C2 (ru) 2005-04-11 2006-04-10 1н-хиназолин-2,4-дионы
PT06724185T PT1871749E (pt) 2005-04-11 2006-04-10 1h-quinazolino-2,4-dionas e sua utilização como ligandos dos receptores ampa
PCT/EP2006/003251 WO2006108591A1 (en) 2005-04-11 2006-04-10 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands
HRP20120867TT HRP20120867T1 (hr) 2005-04-11 2006-04-10 Selurampanel
JO200693A JO2770B1 (en) 2005-04-11 2006-04-10 Organic compounds
HK08103724.9A HK1113790B (en) 2005-04-11 2006-04-10 Selurampanel
PL06724185T PL1871749T3 (pl) 2005-04-11 2006-04-10 Selurampanel
BRPI0608617-9A BRPI0608617A2 (pt) 2005-04-11 2006-04-10 1h-quinazolina-2,4-dionas e seu uso como ligandos de receptor de ampa
ZA200707111A ZA200707111B (en) 2005-04-11 2007-08-23 1H-Quinazoline-2,4-Diones and their use as ampa-receptor ligands
IL185544A IL185544A (en) 2005-04-11 2007-08-27 H1 Quinzoline - 4, 2 - discussions, pharmaceutical preparations that include them and their use in the preparation of drugs
TNP2007000383A TNSN07383A1 (en) 2005-04-11 2007-10-10 1-h-quinazoline-2,4-diones and their use as ampa-receptor ligands
MA30330A MA29411B1 (fr) 2005-04-11 2007-10-29 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
NO20075749A NO20075749L (no) 2005-04-11 2007-11-09 1H-Quinazoline-2,4-diones and their use as ampa-receptor ligands
US12/569,402 US8012988B2 (en) 2005-04-11 2009-09-29 N-(2,4-dioxo-6-(tetrahydrofuran-2-yl)-7-(trifluoromethyl)-1,4-dihydro-2H-quinazolin-3-yl)methanesulfonamide
AU2011200888A AU2011200888B2 (en) 2005-04-11 2011-02-28 1H-Quinazoline-2,4-diones and their use as AMPA-receptor ligands
US13/192,816 US8513268B2 (en) 2005-04-11 2011-07-28 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy
JP2011209578A JP5525500B2 (ja) 2005-04-11 2011-09-26 １ｈ−キナゾリン−２，４−ジオンおよびａｍｐａ受容体リガンドとしてのそれらの使用
ECSP12007795 ECSP12007795A (es) 2005-04-11 2012-04-19 1h-quinazolin-2,4-dionas y su uso como ligandos del receptor de ampa
IL220682A IL220682A (en) 2005-04-11 2012-06-28 1h- quinzulin-4,2-discussions, pharmaceuticals including them and their use in drug preparation
CY20121101042T CY1113573T1 (el) 2005-04-11 2012-10-31 Selurampanel
US13/932,173 US20130296332A1 (en) 2005-04-11 2013-07-01 1h-quinazoline-2,4-diones
HRP20141116TT HRP20141116T1 (hr) 2005-04-11 2014-11-18 1h-kinazolin-2,4-dioni
CY20141100963T CY1115767T1 (el) 2005-04-11 2014-11-19 1η-κιναζολινο-2,4-διονες

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0507298.8A GB0507298D0 (en) 2005-04-11 2005-04-11 Organic compounds

Publications (1)

Publication Number Publication Date
GB0507298D0 true GB0507298D0 (en) 2005-05-18

Family

ID=34610935

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0507298.8A Ceased GB0507298D0 (en) 2005-04-11 2005-04-11 Organic compounds

Country Status (35)

Country Link
US (4) US7655666B2 (enExample)
EP (4) EP2463278A1 (enExample)
JP (2) JP4898783B2 (enExample)
KR (2) KR101162827B1 (enExample)
CN (2) CN102807531A (enExample)
AR (1) AR053047A1 (enExample)
AU (2) AU2006233639B2 (enExample)
BR (1) BRPI0608617A2 (enExample)
CA (1) CA2601986C (enExample)
CY (2) CY1113573T1 (enExample)
DK (2) DK2468732T3 (enExample)
EC (1) ECSP12007795A (enExample)
ES (2) ES2392542T3 (enExample)
GB (1) GB0507298D0 (enExample)
GT (2) GT200600144AA (enExample)
HR (2) HRP20120867T1 (enExample)
IL (2) IL185544A (enExample)
IN (1) IN2012DN00785A (enExample)
JO (1) JO2770B1 (enExample)
MA (1) MA29411B1 (enExample)
MX (1) MX2007012592A (enExample)
MY (2) MY142474A (enExample)
NO (1) NO20075749L (enExample)
NZ (2) NZ560964A (enExample)
PE (2) PE20061306A1 (enExample)
PL (2) PL1871749T3 (enExample)
PT (2) PT1871749E (enExample)
RU (2) RU2435760C2 (enExample)
SA (2) SA06270089B1 (enExample)
SG (1) SG177182A1 (enExample)
SI (2) SI1871749T1 (enExample)
TN (1) TNSN07383A1 (enExample)
TW (2) TWI385158B (enExample)
WO (1) WO2006108591A1 (enExample)
ZA (2) ZA200807421B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
TW200934497A (en) * 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
WO2010046399A1 (en) * 2008-10-22 2010-04-29 Novartis Ag Combinations for the treatment of migraine
CN102470137A (zh) * 2009-07-23 2012-05-23 诺瓦提斯公司 用于治疗神经元蜡样脂褐质沉积症的1h-喹唑啉-2,4-二酮
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
WO2011048150A1 (en) 2009-10-20 2011-04-28 Novartis Ag Use of 1h-quinazoline-2,4-diones
AR079545A1 (es) 2009-12-21 2012-02-01 Bayer Cropscience Ag Tienilpiri(mi)dinilazol
JP2013515076A (ja) * 2009-12-22 2013-05-02 ノバルティス アーゲー 即放性錠剤の形態の１ｈ−キナゾリン−２，４−ジオンａｍｐａ受容体アンタゴニストを含む製剤およびその調製
EP2571865A1 (en) 2010-05-20 2013-03-27 Novartis AG 2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl-sulfonamide derivatives
US20130096145A1 (en) * 2010-06-24 2013-04-18 Novartis Ag Use of 1H-quinazoline-2,4-diones
CN103080102B (zh) 2010-07-09 2016-08-24 拜耳知识产权有限责任公司 作为杀虫剂的邻氨基苯甲酰胺衍生物
EP2668159A1 (en) 2011-01-24 2013-12-04 Novartis AG 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
IN2014DN01791A (enExample) 2011-09-07 2015-05-15 Novartis Ag
WO2014042176A1 (ja) * 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
MA39211B1 (fr) 2013-12-24 2019-01-31 Bristol Myers Squibb Co Composés tricycliques comme agents anti-cancers
JP6667091B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ Ｔｒｐｃ５調節因子としての、精神神経障害の処置のためのキナゾリン−２，４（１ｈ，３ｈ）−ジオン誘導体
SG11202010187RA (en) 2018-05-10 2020-11-27 Zoetis Services Llc Endoparasitic depsipeptides

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US535475A (en) 1895-03-12 Governor
GB281309A (en) 1926-11-27 1928-03-29 Inventia Patent Verwert Ges Improvements in or relating to brushing machines having replaceable brush members
US2957880A (en) 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US2838519A (en) 1953-12-23 1958-06-10 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US3310553A (en) 1962-09-25 1967-03-21 Pfizer & Co C Alkylated thioxathenesulfonamides
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3637661A (en) 1970-03-04 1972-01-25 Ciba Geigy Corp 10-hydroxy-10 11-dihydro-dibenzazepine derivative
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
FI834666A7 (fi) 1982-12-23 1984-06-24 Ciba Geigy Ag Foerfarande foer framstaellning av nya aralkyltriazolfoereningar.
MX7829A (es) * 1986-08-21 1993-08-01 Pfizer Quinazolindionas y piridopirimindionas y procedimiento para su preparacion
KR880007433A (ko) 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5122522A (en) 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
CA2002182C (en) 1989-11-03 2000-06-13 Richard J. Wurtman Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use
IE913473A1 (en) * 1990-10-15 1992-04-22 Fujisawa Pharmaceutical Co Quinazoline derivatives and their preparation
HU219778B (hu) 1990-12-21 2001-07-30 Gyógyszerkutató Intézet Közös Vállalat Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények
DE4234933A1 (de) 1991-10-31 1993-05-06 Asta Medica Ag, 6000 Frankfurt, De Neue phthalazine, die in 1-stellung eine ether- oder thioether-gruppierung enthalten und verfahren zu deeren herstellung
GB9125485D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
WO1993024442A1 (fr) 1992-05-29 1993-12-09 Yamanouchi Pharmaceutical Co., Ltd. Medicament renfermant un derive d'acide benzoique, et nouveau derive d'acide benzoique
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
US5597922A (en) 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore
PT101732B (pt) 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
CA2222713C (en) 1995-07-14 2003-04-22 Andrew John Mcglashan Richards Composition comprising d-threo-methylphenidate and another drug
GB9514451D0 (en) 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
US5773434A (en) 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
GB9604943D0 (en) 1996-03-08 1996-05-08 Chiroscience Ltd Resolution
JP2000511883A (ja) 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
WO1998011892A1 (en) 1996-09-17 1998-03-26 The Regents Of The University Of California Positive ampa receptor modulation to enhance brain neurotrophic factor expression
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
CA2269807C (en) 1996-10-24 2007-04-10 Novartis Ag Substituted aminoalkanephosphonic acids
DE19650975A1 (de) 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
TR199902094T2 (xx) 1997-02-28 1999-12-21 Prizer Products Inc. 3-Heteroareil-4(3H)-kinazolinonlar�n atropizomerleri.
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
GB9721497D0 (en) 1997-10-09 1997-12-10 Ciba Geigy Ag Organic compounds
ATE373957T1 (de) 1997-10-09 2007-10-15 Univ Emory Verfahren und vorrichtung zur transdermalen verabreichung von lithium
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
IL137720A0 (en) * 1998-02-18 2001-10-31 Neurosearch As Compounds and their use as positive ampa receptor modulators
US6100401A (en) 1998-04-20 2000-08-08 Novartris Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
EP1002535A1 (en) 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer
US6162919A (en) 1998-12-03 2000-12-19 Novartis Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
JP2000309585A (ja) 1999-02-26 2000-11-07 Kyorin Pharmaceut Co Ltd ６−置換ヘテロキノリンカルボン酸誘導体とその付加塩及びそれらの製造方法
CN1425008A (zh) * 2000-01-24 2003-06-18 沃尼尔·朗伯公司 3－氨基喹唑啉－2,4－二酮抗菌剂
US7501429B2 (en) 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
CA2489420A1 (en) 2001-06-25 2003-01-03 Buadbo Aps Oncology drug innovation
US20030144234A1 (en) 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
US20060264508A1 (en) 2001-10-16 2006-11-23 Stone Richard A Modulation of ocular growth and myopia by gaba drugs
US7163952B2 (en) 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
MXPA04009496A (es) 2002-03-29 2005-01-25 Yamanouchi Pharma Co Ltd Remedio para glioblastoma.
JP4175846B2 (ja) 2002-08-08 2008-11-05 独立行政法人科学技術振興機構 Ａｍｐａ型グルタミン酸受容体サブユニットの発現による脳腫瘍細胞の増殖と浸潤の抑制
WO2004028634A1 (en) 2002-09-25 2004-04-08 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
WO2004058679A2 (en) 2002-12-20 2004-07-15 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
JP4652816B2 (ja) 2002-12-23 2011-03-16 アイシーエージェン インコーポレイテッド カリウムチャネルモジュレータとしてのキナゾリノン
PT1603893E (pt) 2003-01-29 2008-08-21 Asterand Uk Ltd Antagonistas dos receptores ep4
JP4719681B2 (ja) 2003-09-23 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション キナゾリンカリウムチャネル阻害剤
CA2445743A1 (en) 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20090127944A (ko) 2009-12-14
AR053047A1 (es) 2007-04-18
ES2392542T3 (es) 2012-12-11
AU2011200888B2 (en) 2012-02-02
CY1115767T1 (el) 2017-01-25
IL185544A0 (en) 2008-01-06
NZ590463A (en) 2012-05-25
JP5525500B2 (ja) 2014-06-18
KR101162827B1 (ko) 2012-07-05
DK1871749T3 (da) 2012-11-12
RU2435760C2 (ru) 2011-12-10
AU2011200888A1 (en) 2011-03-24
CA2601986C (en) 2015-03-31
US8012988B2 (en) 2011-09-06
PT2468732E (pt) 2014-11-25
GT200600144A (es) 2006-12-18
US20130296332A1 (en) 2013-11-07
TW200716568A (en) 2007-05-01
US20080153836A1 (en) 2008-06-26
IL220682A0 (en) 2012-08-30
CN102807531A (zh) 2012-12-05
TNSN07383A1 (en) 2009-03-17
MA29411B1 (fr) 2008-04-01
CN101155789A (zh) 2008-04-02
PL2468732T3 (pl) 2015-02-27
HRP20141116T1 (hr) 2015-01-30
ZA200807421B (en) 2010-04-28
ES2524316T3 (es) 2014-12-05
PL1871749T3 (pl) 2013-01-31
US20100144747A1 (en) 2010-06-10
US8513268B2 (en) 2013-08-20
IL185544A (en) 2014-03-31
JO2770B1 (en) 2014-03-15
JP2008536839A (ja) 2008-09-11
NZ560964A (en) 2011-02-25
US20110294818A1 (en) 2011-12-01
CA2601986A1 (en) 2006-10-19
TWI385158B (zh) 2013-02-11
US7655666B2 (en) 2010-02-02
HK1113790A1 (en) 2008-10-17
PE20061306A1 (es) 2006-12-23
ECSP12007795A (es) 2013-01-31
MY142474A (en) 2010-11-30
BRPI0608617A2 (pt) 2010-01-19
SA109300363B1 (ar) 2013-02-06
RU2011131276A (ru) 2013-02-10
RU2509764C2 (ru) 2014-03-20
TWI440461B (zh) 2014-06-11
DK2468732T3 (da) 2014-11-10
MX2007012592A (es) 2007-11-16
KR20070110919A (ko) 2007-11-20
EP2463278A1 (en) 2012-06-13
MY149070A (en) 2013-07-15
IL220682A (en) 2014-03-31
JP2012036203A (ja) 2012-02-23
AU2006233639A1 (en) 2006-10-19
SI1871749T1 (sl) 2012-12-31
NO20075749L (no) 2008-01-11
SI2468732T1 (sl) 2014-12-31
CY1113573T1 (el) 2016-06-22
ZA200707111B (en) 2010-05-26
KR100990783B1 (ko) 2010-10-29
SA06270089B1 (ar) 2010-03-20
EP2476671A1 (en) 2012-07-18
EP2468732B1 (en) 2014-08-20
JP4898783B2 (ja) 2012-03-21
IN2012DN00785A (enExample) 2015-06-26
EP1871749B1 (en) 2012-08-01
WO2006108591A1 (en) 2006-10-19
AU2006233639B2 (en) 2010-12-09
CN101155789B (zh) 2012-08-29
TW201304781A (zh) 2013-02-01
SG177182A1 (en) 2012-01-30
GT200600144AA (es) 2011-12-13
EP2468732A1 (en) 2012-06-27
RU2007141566A (ru) 2009-05-20
HRP20120867T1 (hr) 2012-11-30
EP1871749A1 (en) 2008-01-02
PT1871749E (pt) 2012-11-14
PE20091366A1 (es) 2009-09-21

Similar Documents

Publication Publication Date Title
GB0507575D0 (en) Organic compounds
GB0500435D0 (en) Organic compounds
GB0507696D0 (en) Organic compounds
GB0500785D0 (en) Organic compounds
GB0508319D0 (en) Organic compounds
GB0505969D0 (en) Organic compounds
GB0502358D0 (en) Organic compounds
GB0507577D0 (en) Organic compounds
GB0505219D0 (en) Organic compounds
GB0504850D0 (en) Organic compounds
GB0507298D0 (en) Organic compounds
GB0504194D0 (en) Organic compounds
GB0510810D0 (en) Organic compounds
GB0504544D0 (en) Organic compounds
GB0501237D0 (en) Organic compounds
GB0508992D0 (en) Organic compounds
GB0500784D0 (en) Organic compounds
GB0511066D0 (en) Organic compounds
GB0504203D0 (en) Organic compounds
GB0507695D0 (en) Organic compounds
GB0500020D0 (en) Organic compounds
GB0511063D0 (en) Organic compounds
GB0505541D0 (en) Organic compounds
GB0511065D0 (en) Organic compounds
GB0511684D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)